FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3190661875> ?p ?o ?g. }

• W3190661875 endingPage "1648" @default.
• W3190661875 startingPage "1638" @default.
• W3190661875 abstract "MW33 is a fully humanized IgG1κ monoclonal neutralizing antibody, and may be used for the prevention and treatment of coronavirus disease 2019 (COVID-19). We conducted a randomized, double-blind, placebo-controlled, single-dose, dose-escalation Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of MW33. Healthy adults aged 18–45 years were sequentially enrolled into the 4, 10, 20, 40, and 60 mg/kg dose groups and infused with MW33 over 60 ± 15 min and followed for 85 days. All 42 enrolled participants completed the MW33 infusion, and 40 participants completed the 85-day follow-up period. 34 participants received a single infusion of 4 (n = 2), 10 (n = 8), 20 (n = 8), 40 (n = 8), and 60 mg/kg (n = 8) of MW33. 27 subjects in the test groups experienced 78 adverse events (AEs) post-dose, with an incidence of 79.4% (27/34). The most common AEs included abnormal laboratory test results, vascular and lymphatic disorders, and infectious diseases. The severity of AEs was mainly Grade 1 (92 AEs), and three Grade 2 and one Grade 4. The main PK parameters, maximum concentration (Cmax), and area under the concentration-time curve (AUC0–t, and AUC0–∞) in 34 subjects showed a linear kinetic relationship in the range of 10–60 mg/kg. The plasma half-life was approximately 25 days. The positive rates of serum ADAs and antibody titres were low with no evidence of an impact on safety or PK. In conclusion, MW33 was well-tolerated, demonstrated linear PK, with a lower positive rate of serum ADAs and antibody titres in healthy subjects.Trial registration: ClinicalTrials.gov identifier: NCT04427501.Trial registration: ClinicalTrials.gov identifier: NCT04533048.Trial registration: ClinicalTrials.gov identifier: NCT04627584." @default.
• W3190661875 created "2021-08-16" @default.
• W3190661875 creator A5006918835 @default.
• W3190661875 creator A5007364216 @default.
• W3190661875 creator A5018674059 @default.
• W3190661875 creator A5019443348 @default.
• W3190661875 creator A5021236152 @default.
• W3190661875 creator A5035282947 @default.
• W3190661875 creator A5045999468 @default.
• W3190661875 creator A5046267411 @default.
• W3190661875 creator A5047255627 @default.
• W3190661875 creator A5054862750 @default.
• W3190661875 creator A5057109209 @default.
• W3190661875 creator A5063558894 @default.
• W3190661875 creator A5065746649 @default.
• W3190661875 creator A5083338149 @default.
• W3190661875 creator A5083674863 @default.
• W3190661875 creator A5083832879 @default.
• W3190661875 creator A5085346299 @default.
• W3190661875 date "2021-01-01" @default.
• W3190661875 modified "2023-09-28" @default.
• W3190661875 title "Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody" @default.
• W3190661875 cites W2012505332 @default.
• W3190661875 cites W2912112623 @default.
• W3190661875 cites W3001465255 @default.
• W3190661875 cites W3001897055 @default.
• W3190661875 cites W3004280078 @default.
• W3190661875 cites W3009155534 @default.
• W3190661875 cites W3027630905 @default.
• W3190661875 cites W3032255042 @default.
• W3190661875 cites W3034523319 @default.
• W3190661875 cites W3044609992 @default.
• W3190661875 cites W3046641417 @default.
• W3190661875 cites W3046724041 @default.
• W3190661875 cites W3096658347 @default.
• W3190661875 cites W3099753556 @default.
• W3190661875 cites W3111431752 @default.
• W3190661875 cites W3112311859 @default.
• W3190661875 cites W3115009914 @default.
• W3190661875 doi "https://doi.org/10.1080/22221751.2021.1960900" @default.
• W3190661875 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8382006" @default.
• W3190661875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34346827" @default.
• W3190661875 hasPublicationYear "2021" @default.
• W3190661875 type Work @default.
• W3190661875 sameAs 3190661875 @default.
• W3190661875 citedByCount "12" @default.
• W3190661875 countsByYear W31906618752022 @default.
• W3190661875 countsByYear W31906618752023 @default.
• W3190661875 crossrefType "journal-article" @default.
• W3190661875 hasAuthorship W3190661875A5006918835 @default.
• W3190661875 hasAuthorship W3190661875A5007364216 @default.
• W3190661875 hasAuthorship W3190661875A5018674059 @default.
• W3190661875 hasAuthorship W3190661875A5019443348 @default.
• W3190661875 hasAuthorship W3190661875A5021236152 @default.
• W3190661875 hasAuthorship W3190661875A5035282947 @default.
• W3190661875 hasAuthorship W3190661875A5045999468 @default.
• W3190661875 hasAuthorship W3190661875A5046267411 @default.
• W3190661875 hasAuthorship W3190661875A5047255627 @default.
• W3190661875 hasAuthorship W3190661875A5054862750 @default.
• W3190661875 hasAuthorship W3190661875A5057109209 @default.
• W3190661875 hasAuthorship W3190661875A5063558894 @default.
• W3190661875 hasAuthorship W3190661875A5065746649 @default.
• W3190661875 hasAuthorship W3190661875A5083338149 @default.
• W3190661875 hasAuthorship W3190661875A5083674863 @default.
• W3190661875 hasAuthorship W3190661875A5083832879 @default.
• W3190661875 hasAuthorship W3190661875A5085346299 @default.
• W3190661875 hasBestOaLocation W31906618751 @default.
• W3190661875 hasConcept C112705442 @default.
• W3190661875 hasConcept C120665830 @default.
• W3190661875 hasConcept C121332964 @default.
• W3190661875 hasConcept C126322002 @default.
• W3190661875 hasConcept C142724271 @default.
• W3190661875 hasConcept C159654299 @default.
• W3190661875 hasConcept C197934379 @default.
• W3190661875 hasConcept C203014093 @default.
• W3190661875 hasConcept C204787440 @default.
• W3190661875 hasConcept C22979827 @default.
• W3190661875 hasConcept C27081682 @default.
• W3190661875 hasConcept C2778375690 @default.
• W3190661875 hasConcept C2780868878 @default.
• W3190661875 hasConcept C61511704 @default.
• W3190661875 hasConcept C71924100 @default.
• W3190661875 hasConcept C76318530 @default.
• W3190661875 hasConcept C90924648 @default.
• W3190661875 hasConcept C98274493 @default.
• W3190661875 hasConceptScore W3190661875C112705442 @default.
• W3190661875 hasConceptScore W3190661875C120665830 @default.
• W3190661875 hasConceptScore W3190661875C121332964 @default.
• W3190661875 hasConceptScore W3190661875C126322002 @default.
• W3190661875 hasConceptScore W3190661875C142724271 @default.
• W3190661875 hasConceptScore W3190661875C159654299 @default.
• W3190661875 hasConceptScore W3190661875C197934379 @default.
• W3190661875 hasConceptScore W3190661875C203014093 @default.
• W3190661875 hasConceptScore W3190661875C204787440 @default.
• W3190661875 hasConceptScore W3190661875C22979827 @default.
• W3190661875 hasConceptScore W3190661875C27081682 @default.
• W3190661875 hasConceptScore W3190661875C2778375690 @default.
• W3190661875 hasConceptScore W3190661875C2780868878 @default.

• next